Showing 4961-4970 of 8839 results for "".
- Mount Sinai Researcher Identifies Single Gene Biomarker to Differentiate Between Atopic Dermatitis and Psoriasishttps://practicaldermatology.com/news/mount-sinai-researcher-identifies-single-gene-biomarker-to-differentiate-between-atopic-dermatitis-and-psoriasis/2460472/Mount Sinai researchers have pinpointed a single gene biomarker, nitride oxide synthase 2 (NOS2) that can distinguish atopic dermatitis (AD) and psoriasis with 100 percent accuracy using adhesive tape strips, a non-invasive alternative to skin biopsy. The study, published in the Jou
- Tremfya is First IL-23 Inhibitor Approved for PsAhttps://practicaldermatology.com/news/tremfya-is-first-il-23-inhibitor-approved-for-psa/2460471/FDA has approved Tremfya® (guselkumab) from Janssen Pharmaceutical Companies of Johnson & Johnson for adult patients with active psoriatic arthritis (PsA). Tremfya is the first interleukin (IL)-23 approved for active PsA. The safety and efficacy of
- Arcutis’ Roflumilast Cream Could Be “Game Changer” for Plaque Psoriasishttps://practicaldermatology.com/news/arcutis-roflumilast-cream-could-be-game-changer-for-plaque-psoriasis/2460467/Arcutis Biotherapeutics, Inc.’s Roflumilast cream (ARQ-151) produced significant improvements in patients with plaque psoriasis in as early as two weeks, according to a results from a phase 2b trial published in The New E
- Arcutis Initiates Patient Enrollment in Phase 2b Study in Chronic Hand Eczemahttps://practicaldermatology.com/news/arcutis-initiates-patient-enrollment-in-phase-2b-study-in-chronic-hand-eczema/2460466/Arcutis Biotherapeutics, Inc. initiated enrollment in the Phase 2b portion of the Phase 1/2b study of ARQ-252, a potent and highly selective topical small molecule inhibitor of Janus kinase type 1 (JAK1), in adult patients with chronic hand eczema. Topline data from this trial are expected in the
- Azitra Awarded Patent for Engineered Bacterial Strain Discovery Platformhttps://practicaldermatology.com/news/azitra-awarded-patent-for-engineered-bacterial-strain-discovery-platform/2460463/Azitra, Inc. has been issued a patent for the company’s engineered bacterial strain discovery platform. The United States Patent and Trademark Office (USPTO) has issued US Patent No. 10,702,558, which includes broad composition of matter claims that are central to the the company’s pr
- Leo Pharma: FDA Accepts BLA for Tralokinumab for ADhttps://practicaldermatology.com/news/leo-pharma-fda-accepts-bla-for-tralokinumab-for-ad/2460462/The FDA has accepted the Biologics License Application (BLA) for Leo Pharma’s tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD), the company says. A taget action date has been set in the second quarter of 2021. Tralokinumab is a fully human mo
- Allergan Helps Bridge the Gender Gap in STEMhttps://practicaldermatology.com/news/allergan-helps-bridge-the-gender-gap-in-stem/2460460/Allergan has pledged $300K to support STEM Education through their partnership with Girls Inc. In addition to the donation, Allergan is also offering mentoring initiatives and resources to educate and emp
- Pulse Biosciences, Inc.’s Nano-Pulse Stimulation Technology Produces Favorable Results for Warts and Allhttps://practicaldermatology.com/news/pulse-biosciences-incs-nano-pulse-stimulation-technology-produces-favorable-results-for-warts-and-all/2460457/Three studies show positive results for Pulse Biosciences, Inc.’s investigational use of Nano-Pulse Stimulation non-thermal energy in nodular basal cell carcinoma (BCC), sebaceous hyperplasia (SH) lesions and cutaneous non-genital warts. In addition, pre-clinical observations of t
- Evolus Loses Round 1 in Trade Battle with AbbVie's Allerganhttps://practicaldermatology.com/news/evolus-loses-round-1-in-trade-battle-with-abbvies-allergan/2460455/Evolus' and Daewoong Pharma's Jeuveau lost the first round in a trade dispute with AbbVie's Allergan and its Korean partner Medytox that sought to block imports of the Botox rival, but the match is not over yet. AbbVie's Allergan and its Korean partner Medytox
- FDA Oks Endo's Anti-Cellulite Injectablehttps://practicaldermatology.com/news/fda-oks-endos-anti-cellulite-injectable/2460454/The FDA has given its nod to an entirely new way to address cellulite. Endo Aesthetic’s Qwo (collagenase clostridium histolyticum-aaes) is the first injectable treatment for moderate to severe cellulite of the buttocks in adult women. When fat in cellulite-prone areas swells and e